Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)

NCT04632940 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT04632940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04632940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
Kyntra Bio
Phase
Phase 3
Overall status
Terminated
Start date
March 3, 2021
Completion date
December 14, 2023
Enrollment
73 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy